Medical/Pharmaceuticals

Alterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021

MELBOURNE, Australia, Nov. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced a poster presentation and accompanying vi...

2021-11-09 20:30 1257

FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer

SYDNEY, Nov. 9, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that an Investigational New Drug application (IND) for a trial of PXS-5505 in hepatocellular carcinoma (HCC) patients has been cleared by the United States Food and Drug Administr...

2021-11-09 19:00 1165

Regrowing Damaged Body Parts: How Osteopore, an Australian-listed Company, is Making it Accessible

SINGAPORE, Nov. 9, 2021 /PRNewswire/ -- Osteopore, an Australian and Singapore based leader in regenerative implants on a commercial scale, is developing technology that enables widespread adoption of tissue engineering. Despite the global average life expectancy rising by more than 6 years betwe...

2021-11-09 18:05 1340

Antengene to Release Preliminary Results of Selinexor for the Treatment of Peripheral T-Cell Lymphoma and NK/T-Cell Lymphoma at the 2021 ASH Annual Meeting

SHANGHAI and HONG KONG, Nov. 9, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2021-11-09 16:30 2194

Standigm Established a Synthetic Research Center to Improve Efficiency of AI Drug Discovery

SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, announced today that the company had established a Synthetic Research Center in the headquarters of SK Chemicals Co., Ltd ("SK Chemicals", KRX 285...

2021-11-09 10:47 1795

Recbio Announces New Study Showing Its COVID-19 Vaccine Induced High Levels of Neutralizing Antibodies against SARS-CoV-2 and Variants of Concern

TAIZHOU, China, Nov. 9, 2021 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. ("Recbio"), a biopharmaceutical company focusing on the research, development and commercialization of innovative vaccines that can address prevalent diseases with significant burden, today announced preclinical data...

2021-11-09 10:00 2297

Sustained Hepatitis B Surface Antigen Loss in Chronic Hepatitis B Patients with Subcutaneous PD-L1 Antibody ASC22 Treatment: Interim Results of Phase IIb Study

HANGZHOU, China and SHAOXING, China, Nov. 9, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today that the interim results of 44 chronic hepatitis B (CHB) patients from a Phase IIb trial of ASC22 (Envafolimab), a subcutaneously administered PD-L1 antibody (ClinicalTrials.gov Ide...

2021-11-09 08:33 2459

CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics

* The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and DotBio will lead the design and engineering of the mole...

2021-11-09 08:05 3818

BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration, at the CTAD Meeting in Boston

BOSTON, Nov. 5, 2021 /PRNewswire/ -- South Korean bio-venture BIORCHESTRA Co. Ltd., is an RNA therapeutics firm focused on neurodegeneration.  BIORCHESTRA discovered a disease-associated microRNA that was found to be significantly up-regulated in samples from Alzheimer's disease patients. It then...

2021-11-08 22:59 2629

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in Metastatic ER+/HER2- Breast Cancer

SUZHOU, China, and ROCKVILLE, Md., Nov. 8, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced a clinical trial collaborati...

2021-11-08 21:47 2025

BARDA and Clarivate Partner to Identify Therapeutics Which Can Be Repurposed as Medical Countermeasures to Chemical Exposure

LONDON, Nov. 8, 2021 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced a new partnership with the Biomedical Advanced Research and Development Authority (BARDA), which provides an integra...

2021-11-08 21:00 2374

I-Mab and Roche Diagnostics Announce Strategic Collaboration to Co-Develop Companion Diagnostics Solutions for I-Mab's Innovative Pipeline at the 4th CIIE

SHANGHAI and GAITHERSBURG, Md., Nov. 8, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Company has entered into a strategic collaborati...

2021-11-08 21:00 1590

RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill

TEL AVIV, Israel and RALEIGH, NC, Nov. 8, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into a strategic agreement with Kukbo Co. Lt...

2021-11-08 20:00 2079

RadLink, Singapore's Leading Imaging Center, Adapts Lunit AI to Analyze Chest X-rays and Mammograms

SEOUL, South Korea, Nov. 8, 2021 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with RadLink, a subsidiary of the Fullerton Health Group,Singapore's leading private diagnostic and molecular imaging service provider. As a leading medical AI company, Lunit provides AI software th...

2021-11-08 14:36 3311

Ascletis and Suzhou Alphamab Expand their Partnership into Worldwide License Agreement for ASC22 (Envafolimab) to Treat Hepatitis B and Other Viral Diseases

HANGZHOU, China and SHAOXING, China and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK) and Suzhou Alphamab Co., Ltd. (Suzhou Alphamab) jointly announce today that Ascletis' subsidiary and Suzhou Alphamab have entered into an exclusive and worldwide license agreement ou...

2021-11-08 08:30 2383

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 8, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:15 2282

Everest Medicines Announces Up to HK$100 million Additional Share Repurchase Program

SHANGHAI, Nov. 7, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inAsia, today announced that i...

2021-11-08 08:10 1662

Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications

SAN FRANCISCO and SUZHOU, China, Nov. 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...

2021-11-08 08:00 2583

Bugworks Research Announces the First in Human Phase 1 Study of BWC0977 for the Treatment of Critical Bacterial Infections

BANGALORE, India; SARATOGA, Calif. and ADELAIDE, Australia, Nov. 8, 2021 /PRNewswire/ -- Bugworks research today announced that the first human dose was administered in a Phase 1 clinical trial evaluating BWC0977: a next generation broad-spectrum, novel bacterial topoisomerase inhibitor (NBTI), s...

2021-11-08 07:00 5312

Wegovy™ Demonstrated Significant and Sustained Weight Loss in Two-Year Study in Adults With Obesity

* The STEP 5 trial demonstrated an average weight loss of 15.2% with Wegovy™ at 104-weeks when used with a reduced calorie meal plan and increased physical activity vs. 2.6% with placebo * The trial also showed that 77.1% of study participants who received Wegovy™ lost at least 5% of their bo...

2021-11-05 20:58 2712
1 ... 309310311312313314315 ... 573

Week's Top Stories